Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.verified

GLUE

Price:

$5.865

Market Cap:

$359.95M

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in he...[Read more]

Industry

Biotechnology

IPO Date

2021-06-24

Stock Exchange

NASDAQ

Ticker

GLUE

The Enterprise Value as of September 2024 (TTM) for Monte Rosa Therapeutics, Inc. (GLUE) is 295.46M

According to Monte Rosa Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 295.46M. This represents a change of 11.85% compared to the average of 264.16M of the last 4 quarters.

Monte Rosa Therapeutics, Inc. (GLUE) Historical Enterprise Value (quarterly & annually)

How has GLUE Enterprise Value performed in the past?

The mean historical Enterprise Value of Monte Rosa Therapeutics, Inc. over the last ten years is 609.76M. The current 295.46M Enterprise Value has changed 4.75% with respect to the historical average. Over the past ten years (40 quarters), GLUE's Enterprise Value was at its highest in in the March 2021 quarter at 963.74M. The Enterprise Value was at its lowest in in the June 2021 quarter at -241958424.20.

Quarterly (TTM)
Annual

Average

609.76M

Median

604.19M

Minimum

208.33M

Maximum

958.04M

Monte Rosa Therapeutics, Inc. (GLUE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Monte Rosa Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 3.38%

Maximum Annual Enterprise Value = 958.04M

Minimum Annual Increase = -41.83%

Minimum Annual Enterprise Value = 208.33M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023208.33M-40.73%
2022351.49M-41.83%
2021604.19M-36.93%
2020958.04M3.38%

Monte Rosa Therapeutics, Inc. (GLUE) Average Enterprise Value

How has GLUE Enterprise Value performed in the past?

The current Enterprise Value of Monte Rosa Therapeutics, Inc. (GLUE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

388.00M

5-year avg

609.76M

10-year avg

609.76M

Monte Rosa Therapeutics, Inc. (GLUE) Enterprise Value vs. Peers

How is GLUE’s Enterprise Value compared to its peers?

Monte Rosa Therapeutics, Inc.’s Enterprise Value is less than Nkarta, Inc. (361.72M), greater than Lyell Immunopharma, Inc. (237.84M), greater than Generation Bio Co. (230.64M), less than Sana Biotechnology, Inc. (947.52M), greater than Design Therapeutics, Inc. (272.10M), greater than Werewolf Therapeutics, Inc. (-5104292.00), greater than Ikena Oncology, Inc. (47.83M), less than Stoke Therapeutics, Inc. (584.36M), less than Foghorn Therapeutics Inc. (419.29M), greater than Shattuck Labs, Inc. (119.24M), less than Kymera Therapeutics, Inc. (3.13B), less than Nurix Therapeutics, Inc. (1.55B), less than Gracell Biotechnologies Inc. (5.46B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Erasca, Inc. (667.94M),

Build a custom stock screener for Monte Rosa Therapeutics, Inc. (GLUE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monte Rosa Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monte Rosa Therapeutics, Inc. (GLUE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monte Rosa Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Monte Rosa Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Monte Rosa Therapeutics, Inc. (GLUE)?

What is the 3-year average Enterprise Value for Monte Rosa Therapeutics, Inc. (GLUE)?

What is the 5-year average Enterprise Value for Monte Rosa Therapeutics, Inc. (GLUE)?

How does the current Enterprise Value for Monte Rosa Therapeutics, Inc. (GLUE) compare to its historical average?